Riskpilot← Back to searchSign inGet full accessCENEXUM Technologies ApS
APSActiveCVR 43234358Ved Kæret 4Research and experimental development on natural sciences and engineering · NACE 7210Est. 20221 employees
Revenue 2024
DKK 11K
EBITDA margin
100.0%
+160% vs 2023
Equity ratio
95.1%
Financial strength
Net profit 2024
DKK -9K
+61% vs 2023
| Revenue | DKK 11K | — |
| EBITDA | DKK 11K | +160% |
| Net profit | DKK -9K | +61% |
| Total assets | DKK 888K | +669% |
| Equity | DKK 845K | +725% |
| Employees | 1 | — |
Legal name
CENEXUM Technologies ApS
CVR number
43234358
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
29. april 2022
Share capital
DKK 55.412
Employees
1 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af den administrerende direktør og bestyrelsesformanden i forening,
eller af tre bestyrelsesmedlemmer i forening.
Company purpose
Selskabets formål er at udvikle terapeutiske og diagnostiske produkter til CNS og andre nerverelaterede sygdomme samt enhver aktivitet, der efter ledelsens skøn står i forbindelse hermed, idet virksomheden kombinerer microelektronik, microchip-implantater og AI.
Address
Ved Kæret 4
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | 0 | 0 | 11 |
| Staff expenses | -0 | -0 | -0 |
| EBITDA | -26 | -18 | 11 |
| Depreciation & amort. | -0 | -0 | -31 |
| EBIT | -26 | -18 | -21 |
| Net financials | -3 | -5 | 0 |
| Profit before tax | -29 | -23 | -21 |
| Tax | -0 | -0 | -12 |
| Net profit | -29 | -23 | -9 |
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Total assets | 71 | 116 | 888 |
| Equity | 11 | 102 | 845 |
| Long-term debt | 0 | 0 | 0 |
| Short-term debt | 60 | 13 | 38 |
| Total debt | 60 | 13 | 38 |
EBITDA margin
100.0%
This company
15.8%
Market median
+533% vs market
20222024
Equity ratio
95.1%
This company
38.2%
Market median
+149% vs market
20222024
Return on equity
-1.0%
This company
18.4%
Market median
-105% vs market
20222024
Net profit margin
-82.6%
This company
8.1%
Market median
-1120% vs market
20222024
Asset turnover
0.01×
This company
1.12×
Market median
-99% vs market
20222024
Debt / equity
0.05×
This company
0.62×
Market median
+92% vs market
20222024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-04-29 – 2022-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
DB Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2022 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2022 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Aarhus Universitet | Company | 20.0% | 20.0% | 2024 |
| Individual | 10.0% | 10.0% | 2024 | |
Neurologic Holding ApS | Company | 10.0% | 10.0% | 2024 |
LRP Ventures ApS | Company | 10.0% | 10.0% | 2024 |
DBH Bion Holding ApS | Company | 10.0% | 10.0% | 2024 |
HAMICH ApS | Company | 10.0% | 10.0% | 2024 |
| Individual | 5.0% | 5.0% | 2023 | |
Medodan ApS | Company | 5.0% | 5.0% | 2023 |
| Individual | 10.0% | 10.0% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
HAMICH ApS
CENEXUM Technologies ApS Board members of CENEXUM Technologies ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Dennis Bang Henriksen | Chief Executive Officer | 0 companies |
| Mikael Ørum | Chairman | 0 companies |
| Poul Sørensen | Board of Directors | 0 companies |
| Jens Christian Hedemann Sørensen | Board of Directors | 0 companies |